Shanghai RAAS Blood Products vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shanghai RAAS Blood Products Co Ltd Class A (002252.CS)

Q3 202622 Jul – 9 Oct 2026

▲2▼2

RAAS profit slumps, but pipeline and buyback offer support

First-half profit and revenue fall sharply First-half revenue fell 18.79% and net profit dropped 35.8% from a year earlier, with no dividend paid. The whole blood-products industry was weak, and the company carries 8.2 billion yuan of goodwill from past deals, which could hurt earnings if business stays soft.
This is the main force pushing the stock down, showing weaker earnings and balance-sheet risk.
New drug pipeline advances toward market A Phase II trial started for SR604, a first-in-class hemophilia antibody, and it has now entered Phase III. A Protein C trial application was also accepted. These could widen the product line and improve plasma use, though no revenue yet.
Pipeline progress is the main positive driver that could lift future growth and investor sentiment.
Company buys back its own shares RAAS repurchased 17 million shares for about 85.7 million yuan, roughly 0.26% of total shares. Buybacks reduce shares outstanding and signal management sees value, giving some support to the stock price.
The buyback is a concrete capital action that supports the share price.
CFO departure adds uncertainty Chief financial officer Chen Leqi resigned for personal reasons and was replaced by Jiang Lan, who spent over twenty years in the Haier system. A finance chief change during weak results can worry investors about internal stability.
Leadership change at the finance helm is a real counterweight to the positive pipeline news.

August 202622 Jul – 9 Oct 2026

▲2▼2

RAAS profit slumps, but pipeline and buyback offer support

First-half profit and revenue fall sharply First-half revenue fell 18.79% and net profit dropped 35.8% from a year earlier, with no dividend paid. The whole blood-products industry was weak, and the company carries 8.2 billion yuan of goodwill from past deals, which could hurt earnings if business stays soft.
This is the main force pushing the stock down, showing weaker earnings and balance-sheet risk.
New drug pipeline advances toward market A Phase II trial started for SR604, a first-in-class hemophilia antibody, and it has now entered Phase III. A Protein C trial application was also accepted. These could widen the product line and improve plasma use, though no revenue yet.
Pipeline progress is the main positive driver that could lift future growth and investor sentiment.
Company buys back its own shares RAAS repurchased 17 million shares for about 85.7 million yuan, roughly 0.26% of total shares. Buybacks reduce shares outstanding and signal management sees value, giving some support to the stock price.
The buyback is a concrete capital action that supports the share price.
CFO departure adds uncertainty Chief financial officer Chen Leqi resigned for personal reasons and was replaced by Jiang Lan, who spent over twenty years in the Haier system. A finance chief change during weak results can worry investors about internal stability.
Leadership change at the finance helm is a real counterweight to the positive pipeline news.

Latest22 Jul – 9 Oct 2026

▲2▼2

RAAS profit slumps, but pipeline and buyback offer support

First-half profit and revenue fall sharply First-half revenue fell 18.79% and net profit dropped 35.8% from a year earlier, with no dividend paid. The whole blood-products industry was weak, and the company carries 8.2 billion yuan of goodwill from past deals, which could hurt earnings if business stays soft.
This is the main force pushing the stock down, showing weaker earnings and balance-sheet risk.
New drug pipeline advances toward market A Phase II trial started for SR604, a first-in-class hemophilia antibody, and it has now entered Phase III. A Protein C trial application was also accepted. These could widen the product line and improve plasma use, though no revenue yet.
Pipeline progress is the main positive driver that could lift future growth and investor sentiment.
Company buys back its own shares RAAS repurchased 17 million shares for about 85.7 million yuan, roughly 0.26% of total shares. Buybacks reduce shares outstanding and signal management sees value, giving some support to the stock price.
The buyback is a concrete capital action that supports the share price.
CFO departure adds uncertainty Chief financial officer Chen Leqi resigned for personal reasons and was replaced by Jiang Lan, who spent over twenty years in the Haier system. A finance chief change during weak results can worry investors about internal stability.
Leadership change at the finance helm is a real counterweight to the positive pipeline news.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.